EGFR and non-small cell lung carcinoma: A recent meta-analysis also demonstrated that in patients with advanced EGFR-wt NSCLC, conventional chemotherapy was associated with better improvement of PFS compared with first-generation EGFR-TKIs such as gefitinib and erlotinib [23].